Regeneron (REGN) wins $400M in damages as jury finds Amgen (AMGN) violated antitrust laws by promoting its heart drug Repatha ...

Now, Libtayo (cemiplimab) is also in the mix. Sanofi and Regeneron have just halted a 466-patient phase 3 trial of the drug in combination with chemo rarely, saying they saw a significant ...

A federal jury found Amgen liable for violating antitrust and tort laws. Elsewhere, Allogene and Kyverna trimmed staff and ...

Patients were of a median age of 51 years old – 78% with SCC and 22% with adenocarcinoma or adenosquamous carcinoma – and randomised to receive 350mg Libtayo every three weeks or chemotherapy ...

Although the patient population ... point, as Libtayo continues to report growth and the company’s bispecific antibodies post impressive data. Beyond Libtayo, Regeneron's oncology pipeline ...

Regeneron aims to advance cancer treatments through innovative research and partnerships while emphasizing the significance of their PD-1 inhibitor, Libtayo, in ongoing clinical trials.

Regeneron continues to deliver growth on top/bottom line in the near to longer-term with Dupi and Libtayo, the analyst tells investors in a research note.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2025 Earnings Call Transcript April 29, 2025 Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $8.22 EPS ...

Libtayo Global ... potential sales growth. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) faces challenges from increased use of low-cost off-label Avastin due to patient affordability issues.

Regeneron also purchased rights to the collaboration's PD-1 antibody Libtayo, which could serve ... another chronic disease with a large patient population. The company also has an extremely ...

Schleifer attributed the shift to more patients using off-label ... As for the rest of Regeneron’s commercial medicine chest, cancer med Libtayo grew total sales—both in the U.S. and beyond ...